soc

Picarro Achieves ISO/IEC 27001:2022, 27017, and 27018 Certifications and Successfully Completes SOC 2 Type 2 Examination

Compliance with Rigorous International Standards Ensure Picarro Meets the Highest Levels of Data Security, Privacy, and Operational Integrity SANTA CLARA,…

2 weeks ago

PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer

Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…

1 month ago

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…

6 months ago